EP0412105A1 - Stammzellen-hemmungsfaktor - Google Patents

Stammzellen-hemmungsfaktor

Info

Publication number
EP0412105A1
EP0412105A1 EP19890905435 EP89905435A EP0412105A1 EP 0412105 A1 EP0412105 A1 EP 0412105A1 EP 19890905435 EP19890905435 EP 19890905435 EP 89905435 A EP89905435 A EP 89905435A EP 0412105 A1 EP0412105 A1 EP 0412105A1
Authority
EP
European Patent Office
Prior art keywords
inhibitor
cells
sepharose
stem cells
resin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP19890905435
Other languages
English (en)
French (fr)
Inventor
Ian Bernard Pragnell
Gerald Graham
Eric Wright
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Campaign Technology Ltd
Original Assignee
Cancer Research Campaign Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Campaign Technology Ltd filed Critical Cancer Research Campaign Technology Ltd
Publication of EP0412105A1 publication Critical patent/EP0412105A1/de
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • THIS INVENTION relates to stem cell inhibitors and is particularly concerned with improvements in the management of cancer chemotherapy.
  • medullary aplasia represents a limiting factor for the clinical use of cytotoxic drugs which are active in cycling cells during chemotherapy of cancer. It has been recognised for many years that existing methods of chemotherapy could be improved if it were possible to protect the haemopoietic stem cells during treatment with the cytotoxic drug but, in spite of extensive research in this area, no suitably specific inhibitory agent from a readily amenable source has previously been discovered. One of the reasons for this lack of progress is believed to be the difficulty in developing a suitable ii vitro assay to monitor stem cell regulation.
  • the present invention provides a haemopoietic stem cell inhibitor characterised by the following properties: 1.
  • the inhibitor activity is sensitive to degradation with trypsin and the inhibitor is therefore proteinaceous.
  • the inhibitor when partially purified by treatment on an anion-exchanger shows a molecular weight range 45-60 Kd on a molecular weight analysis resin.
  • the inhibitor when purified to a single band on polyacrylamide gel electrophoresis, under reducing conditions, shows a molecular weight range of 8-10 Kd and a slightly higher molecular weight range under non-reducing conditions.
  • the inhibitor is heat-stable as follows:
  • the inhibitor binds to anion-exchangers and can be eluted with a salt gradient at between 0.26 and 0.28 molar NaCl. 6.
  • the inhibitor binds to a Heparin Sepharose affinity chromatography resin and can be eluted from the resin with one molar sodium chloride buffer.
  • the inhibitor binds avidly to Blue Sepharose affinity chromatography resin and can be eluted from the resin with 5M magnesium chloride.
  • L929 cell conditioned medium L929 CM, a source of the growth factor CSF-1
  • AF1-19T CM 10% AF1-19T cell conditioned medium
  • the inhibitor of the present invention is obtainable from several macrophage cell lines. Interest centres initially upon the various known macrophage cell lines of bone marrow origin, typically murine bone marrow as this represents a major source of such macrophage cell lines. Our screening of a population of such cell lines has identified at least two known cell lines capable of producing our inhibitor. In the Examples illustrating this invention, we describe the isolation from one such known macrophage cell line.
  • the inhibitor of the invention can be produced quite simply from the inhibitor-producing macrophage cell line by cultivating the cell line in an appropriate growth medium under conventional conditions, e.g. 37 C, the use of aerobic conditions with 5% v/v carbon dioxide in air provides an ideal growth environment, until the cell concentration is approximately 10 per ml. At this stage, the still growing cells are separated from the growth medium, e.g. by centrifugation or preferably membrane filtration and the inhibitor can then be recovered from the supernatant. In order to demonstrate inhibitor activity, it is desirable that the supernatant first be concentrated, e.g. using membrane dialysis to give a concentration of about 20-fold. The inhibitor can then be isolated from the concentrated supernatant by chromatographic procedures.
  • a first step of purification may include passing the concentrated supernatant over an anion-exchange resin and eluting a fraction using a 0.25-0.30M NaCl solution.
  • a second step of purification may include passing the product from the first step over a
  • Sepharose-Heparin column and eluting a fraction using NaCl solution of molarity at least 1M.
  • a third step of purification may include passing the product from the second step over Sepharose-Blue and eluting a fragment using MgCl 2 solution of molarity at least 3M. This elution gives a product that shows a single band on polyacrylamide gel electrophoresis under reducing conditions.
  • the inhibitor or i munogenically active fragment thereof can also be used as an immunogen to raise antibodies that will recognise part or all of the inhibitor, by immunising a host animal and recovering from the host animal antibodies or antibody producing cells.
  • Such antibodies can be prepared e.g. in rabbits where polyclonal antibodies can be recovered from the serum of the rabbit or can be used as immunogens in mice for the production of monoclonal antibodies by conventional techniques.
  • the present invention also extends to DNA sequences encoding the inhibitor of the invention.
  • DNA is of interest in the production of the inhibitor by recombinant DNA techniques.
  • Such techniques can involve two different approaches. Both approaches require, as a first step, the production of a gene library from the messenger RNA of the macrophage cell line that naturally produces the inhibitor. This involves the production of a complementary DNA expressible in a bacterial or other host cells.
  • a first approach involves the production and use of DNA probes. Limited sequence analysis of the inhibitor will permit the synthesis of oligonucleotides that can be used to probe the DNA library to identify those cDN 's in the library that hybridise with the probe and so permits the identification of the messenger RNA encoding the whole inhibitor.
  • a gene library of human origin can be probed to identify and isolate a DNA encoding an inhibitor of human origin which is expressable, using techniques now well-known, in a host cell system.
  • the inhibitor of the invention In clinical application, it is desirable to target the inhibitor of the invention to the blood-forming tissue. This targetting can be achieved by injecting the inhibitor, normally by infusion or bolus intravenous administration and the present invention extends to pharmaceutical compositions containing the inhibitor and appropriate diluents or carriers suitable for such parenteral administration.
  • the interest in the inhibitor of this invention is not restricted to stem cells specific to the haemopoietic system but extends to other stem cells e.g. epithelial stem cells, making the inhibitor of interest not only in relation to alleviating the side effects of cytotoxic drug therapy on bone marrow cells but also in the treatment of solid tumours.
  • the inhibitor is also of interest in the treatment of leukaemia where leukaemic bone marrow cells are treated vitro or vivo, with inhibitor so that proliferation of normal stem cells is prevented and the proliferating leukaemic cells can then be treated with a cytotoxic agent.
  • J774.2 cells were originally growing in a modified Eagles medium supplemented with 10% foetal calf serum. The cells were subcultured into the medium: Dulbeccos x 10 50 ml
  • the 774.2 cells were subcultured into the above medium with added foetal calf serum (5%) for one week, with a further subculture at three days in the same medium. Cells were further subcultured into medium plus 2.5% foetal calf serum for a week, then into 1% foetal calf serum for a further week until finally all serum was removed. At this stage the cells were subcultured every two days, allowed to grow to a concentration of 8 x 10 /ml and diluted to 2 x 10 /ml at subculture. Cells were then transferred to spinner culture and acclimatised to growth in suspension, subcultering every two days as described above. This cell line designated J774.2(S) and capable of growth in serum free suspension culture was then used for inhibitor production.
  • Undiluted medium from 8 x 10 cells is separated from the cells using a Millipore Pellicon-Casette system with a 0.45u microporous membrane.
  • the medium minus cells is then concentrated inthe same apparatus using a 10K cut-off membrane to a final volume of about 400 ml. This concentrate is then processed as described below for biochemical purification.
  • Stage 1 The 400 ml concentrate is desalted on a G-25 HR16/50 (Pharmacia) in 0.02M Tris-HCl pH 7.6, applied to the anion-exchange Mono Q HRlO/10 column (Pharmacia, FPLC system) and finally eluted with a salt gradient (0 to 1M NaCl) in the same buffer.
  • the active fractions of inhibitor elute between 0.26 and 0.28M NaCl.
  • Stage 2 The impure inhibitor from Stage 1 is applied directly to a Sepharose-Heparin (Pharmacia) column, HRlO/10.
  • the inhibitor binds to the resin and the majority of proteins (more than 90%) can be washed off the resin using 0.1M NaCl-0.02M Tris HC1, pH 7.6.
  • the inhibitor is thn eluted from the resin in 1M NaCl-0.02M Tris HC1, pH 7.6.
  • Stage 3 The partially purified inhibitor from Stage 2 is applied directly to a Blue Sepharose (Pharmacia) column HR5/5 without desalting. The column is then washed with the buffer used to elute the inhibitor in Stage 2, to remove other protein. The purified inhibitor, which binds strongly, is eluted with 5M MgCl 2 -0.02M Tris-HCl pH 7.6
  • the purified inhibitor can be seen as a single band of molecular weight 8-10Kd on polyacrylamide gels under reducing conditions. When the inhibitor is applied to polyacrylamide gel electrophoresis under non-reducing conditions, it can be seen to be of slightly higher molecular weight.
  • CFU-A ultipotential stem cells
  • Bone marrow cells were incubated in paired tubes containing 5 x 10 cells in 1 ml Fischer's medium supplemented with 20% horse serum. The inhibitor or alpha-MEM was added to each tube and Fischer's medium was added to control tubes. The mixtures were incubated at

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
EP19890905435 1988-04-21 1989-04-21 Stammzellen-hemmungsfaktor Ceased EP0412105A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8809419 1988-04-21
GB888809419A GB8809419D0 (en) 1988-04-21 1988-04-21 Stem cell inhibitors

Publications (1)

Publication Number Publication Date
EP0412105A1 true EP0412105A1 (de) 1991-02-13

Family

ID=10635573

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19890905435 Ceased EP0412105A1 (de) 1988-04-21 1989-04-21 Stammzellen-hemmungsfaktor

Country Status (4)

Country Link
EP (1) EP0412105A1 (de)
JP (1) JPH03505575A (de)
GB (1) GB8809419D0 (de)
WO (1) WO1989010133A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150328A (en) 1986-07-01 2000-11-21 Genetics Institute, Inc. BMP products
GB9312344D0 (en) * 1993-06-15 1993-07-28 British Bio Technology Pharmaceutical formulations
DE69430059T2 (de) * 1993-06-15 2002-11-14 British Biotech Pharmaceuticals Ltd., Cowley Freisetzung und Mobilisierung hämatopoietischer Zellen
US6291206B1 (en) 1993-09-17 2001-09-18 Genetics Institute, Inc. BMP receptor proteins
DE69434651T2 (de) 1993-12-07 2007-03-08 Genetics Institute, Inc., Cambridge Bmp-12, bmp-13 und diese enthaltende sehne-induzierende zusammensetzungen
WO1999036441A2 (en) * 1998-01-17 1999-07-22 Telistar International Haemopoietic stem cell inhibitor(s)
US6727224B1 (en) 1999-02-01 2004-04-27 Genetics Institute, Llc. Methods and compositions for healing and repair of articular cartilage
PT1223990E (pt) 1999-10-15 2004-12-31 Fidia Advanced Biopolymers Srl Formulacoes de acido hialuronico para administracao de proteinas osteogenicas
EP1399023B1 (de) 2001-06-01 2008-04-30 Wyeth Zusammensetzungen für die systemische verabreichung von sequenzen, die für knochenmorphogenese-proteinen kodieren
TWI267378B (en) 2001-06-08 2006-12-01 Wyeth Corp Calcium phosphate delivery vehicles for osteoinductive proteins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO8910133A1 *

Also Published As

Publication number Publication date
WO1989010133A1 (en) 1989-11-02
JPH03505575A (ja) 1991-12-05
GB8809419D0 (en) 1988-05-25

Similar Documents

Publication Publication Date Title
Burgess et al. Stimulation by human placental conditioned medium of hemopoietic colony formation by human marrow cells
KR0184235B1 (ko) 거핵구 형성 인자
CN1143372A (zh) 血细胞生成成熟因子
JPH01502397A (ja) Ｍ―ｃｓｆの生産方法
KR100439290B1 (ko) 인터로이칸-18을인식하는신규의폴리펩티드
US5599708A (en) Osteoclast growth regulating factors and antibodies
US6417338B1 (en) Autotaxin: motility stimulating protein useful in cancer diagnosis and therapy
JPH08508884A (ja) マクロファージ炎症蛋白変種
WO1991008231A1 (en) [Ala IL-8]77 AS A LEUKOCYTE ADHESION INHIBITOR
CA2132219A1 (en) Novel antler-derived bone growth factors
WO1995032221A9 (en) Autotaxin: motility stimulating protein useful in cancer diagnosis and therapy
EP0412105A1 (de) Stammzellen-hemmungsfaktor
CN112625137B (zh) 一种人白细胞介素10-Fc融合蛋白及其医药用途
US5393534A (en) Liver-derived tumor cell growth inhibitor
JPH10500850A (ja) インターロイキン−６ スプライス変異体
JPH06107693A (ja) 蛋白質とその蛋白質をコードするｄｎａ並びにその蛋白質の製造方法
AU689560B2 (en) Method for stimulating profileration of colon cells using POMC-76-103
AU601168B2 (en) Novel cell growth regulatory factor
JP2863265B2 (ja) インターロイキン１インヒビター
IE83449B1 (en) Cell growth inhibitors
JP2690956B2 (ja) 生体由来のタンパク質
WO1992017500A1 (fr) Nouveau facteur d'amplification de megacaryocytes et son procede de production
JP2000505643A (ja) レクチン様性質を有する化合物およびその生物学的応用
JP2697725B2 (ja) 悪性腫瘍治療用キット
US20030153730A1 (en) Autotaxin: motility stimulating protein useful in cancer diagnosis and therapy

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19901012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17Q First examination report despatched

Effective date: 19921221

RIN1 Information on inventor provided before grant (corrected)

Inventor name: WRIGHT, ERIC

Inventor name: PRAGNELL,IAN,BERNARD

Inventor name: GRAHAM, GERALD

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CANCER RESEARCH CAMPAIGN TECHNOLOGY LTD.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 19940327